Susan Chessa
Family · Guilford, MENPI 1457541773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 24.6% of the total. Among family clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$403
- Novo Nordisk$142
- Bayer$140
- Astellas Pharma US Inc$133
- AstraZeneca$118
- Lundbeck LLC$98
- plus $606 from 12 others
What the payments were for
- Food & beverage$1,49091%
- Education$1499%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $403 |
| Novo Nordisk | 9 | $142 |
| Bayer | 9 | $140 |
| Astellas Pharma US Inc | 3 | $133 |
| AstraZeneca | 7 | $118 |
| Lundbeck LLC | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 6 | $93 |
| Boehringer Ingelheim | 6 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $75 |
| GSK | 4 | $67 |
| Merck | 3 | $51 |
| Pfizer | 3 | $47 |
| Exact Sciences | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Novartis | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$1,639 in reported general payments places this provider in the 90th percentile of 545 family providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $401 |
| Gabapentin | 15 | $367 |
| Valsartan | 11 | $291 |
| Losartan Potassium | 19 | $169 |
| Atorvastatin Calcium | 11 | $165 |
| Metoprolol Succinate | 13 | $160 |
| Metformin Hcl | 16 | $111 |
| Levothyroxine Sodium | 12 | $106 |
| Doxycycline Hyclate | 11 | $93 |
| Furosemide | 15 | $61 |
| Hydrochlorothiazide | 11 | $40 |
| Prednisone | 11 | $37 |
| Lisinopril | 11 | $29 |
| Omeprazole | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other family in Guilford
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
- Natalie BubierLewiston$5K
- Holly JamesYork$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.